Detailed Narrative
Q1 FY25 Performance Overview and Red Sea Impact
Blue Jet Healthcare reported Q1 FY25 revenue of INR 163 crores, marking an 11% decline from Q4 FY24. This dip was primarily attributed to the Red Sea situation, which extended transit times from 35-40 days to 65-70 days, delaying revenue recognition despite production and dispatches exceeding previous quarter levels. The company's profitability remained strong with an annualized ROCE of 22%, EBITDA margin at 27.2%, and PAT margin at 23%, marginally higher than Q4 FY24. Inventory days increased to 204 days from 136 days in Q4 FY24 due to goods in transit, with approximately INR 80 crores of sales not recognized.
Strategic Capacity Expansion and Commercialization
The company is aggressively expanding its manufacturing capabilities. In June 2024, 120KL capacity for cardiovascular drug intermediates was added in Unit II Ambernath, currently in validation. An additional 70-80 KL capacity for Contrast Media Intermediate (MRI space) is expected to go commercial by Q3 FY25. Furthermore, a small volume plant in Unit II is planned for commissioning in Q1 FY26, and backward integration capacity for contrast media in Unit III Mahad is also on track for Q1 FY26. Overall, Blue Jet Healthcare aims to add 40-50% more capacity over the next 12-18 months.
Product Pipeline and Segment Focus
Blue Jet Healthcare maintains a robust product pipeline across its Contrast Media, High-Intensity Sweeteners, and CRAMS segments. In Contrast Media, the company is forward integrating into advanced iodinated intermediates. A new salt, calcium saccharine, has been commercialized in the sweetener segment. For the CRAMS business, 7-8 opportunities with innovators for oncology and CNS are in advanced discussions, with a focus on amino acid-based derivatives. Management expressed high confidence in securing new products to sustain growth in the medium to long term.
Financial Health and Capital Management
The company continues to demonstrate strong financial health, remaining debt-free with cash treasury investments exceeding INR 380 crores. Capital expenditure in Q1 FY25 amounted to INR 90 crores. Blue Jet Healthcare has committed another INR 200 crores for capex over the next 12-18 months, with an anticipated annual capex of INR 100 crores for the next 2-3 years. Management targets sustaining existing EBITDA and PAT margin levels and expects a 3-4 times asset turn on incremental investments.
Gross Margin Drivers and Accounting Policy Change
Despite a 42% QoQ decline in Contrast Media revenue, the gross profit margin improved by 140 basis points. This was attributed to a slight reduction in key raw material prices, increased volume and higher margins for another contrast media product, operational efficiencies, and a technical impact from higher goods in transit. The company also changed its depreciation accounting policy from WDB to straight-line method, resulting in a lower depreciation charge of INR 3.5 crores in Q1 FY25 compared to INR 7.7 crores in Q4 FY24.
Sustainability Initiatives
Blue Jet Healthcare is committed to reducing its carbon footprint and GHG emissions. The company's solar plant, commissioned last year, combined with windmills, now generates approximately 70% of its energy from renewable sources. They also prioritize atom efficiency in chemistries and environmentally friendly plant designs, reflecting a strong focus on sustainable operations.